Lattice Medical occupies a novel position in breast reconstruction by replacing permanent silicone implants or autologous flap surgery with a temporary 3D printed scaffold. The implant, branded MatrixSafe, is designed to be fully resorbed by the body over approximately 18 months, during which the patient's own adipose tissue regenerates into the scaffold. This approach aims to avoid the long-term complications of foreign-body implants and the surgical morbidity of tissue transfer.
The core technology is a material extrusion (MEX) bioprinting process that fabricates a bioresorbable chamber from polylactic acid and caprolactone biopolymer. The scaffold is implanted in a single procedure and gradually degrades as natural tissue fills the void. Lattice Medical operates its own controlled manufacturing facility, which has been operational since 2020, to produce the implants under regulated conditions.
Target customers include oncological surgeons and hospitals performing breast reconstruction after mastectomy. The company is conducting clinical trials across seven centers in France and Spain, with support from Bpifrance's France 2030 program. If approved, the implant would compete against traditional silicone implants from established manufacturers and autologous reconstruction techniques, offering a middle ground that avoids permanent hardware and donor-site damage.
Lattice Medical has raised approximately €63.4 million in total funding, including a €43 million Series B round in 2025 led by the Bpifrance SPI Fund and the EIC Fund. The company's key challenge is demonstrating long-term safety and efficacy in clinical trials, as well as scaling manufacturing to meet regulatory standards for a resorbable Class III medical device. Its success would redefine the standard of care in soft tissue repair.
Competitive Intelligence
Competitors, SWOT analysis, and investment insights